Tang Capital Management DVAX Position
Exited6-Fund ConvergenceTang Capital Management exited their position in Dynavax Technologies Corporation (DVAX) in Q1 2024, after holding the stock for 5 quarters.
The position was first reported in Q1 2023 and has been tracked across 5 quarterly 13F filings.
DVAX is a convergence signal: 6 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 2 readout for rF1V-1018 in 43 days (May 29, 2026), making the timing of Tang Capital's position particularly relevant.
Short interest stands at 13.2% of float with 2.8 days to cover, indicating significant bearish positioning against the stock.
About Dynavax Technologies Corporation
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.
Full company profile →Short Interest
13.2%
2.8 days to cover
Tang Capital Management DVAX Position History
Frequently Asked Questions
Does Tang Capital Management own DVAX?
No. Tang Capital Management exited their position in Dynavax Technologies Corporation (DVAX) in Q1 2024. They previously held the stock for 5 quarters.
How many hedge funds own DVAX?
6 specialist biotech hedge funds currently hold DVAX, including Deep Track Capital, Deerfield Management, Eventide Asset Management and 3 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Tang Capital Management first buy DVAX?
Tang Capital Management's position in DVAX was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Tang Capital Management's DVAX position increasing or decreasing?
Tang Capital Management completely exited their DVAX position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
DVAXCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Tang Capital ManagementPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →